Sonnet BioTherapeutics Ownership 2024 | Who Owns Sonnet BioTherapeutics Now?
Institutional Ownership
0.05%
Insider Ownership
5.44%
Retail Ownership
94.51%
Institutional Holders
1.00
Sonnet BioTherapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ANSON FUNDS MANAGEMENT LP | 40.87% | 0.10% | 1,760,000 | 1,760,000 | 100.00% | 633,600,000 | Mar 31, 2023 |
WALLEYE CAPITAL LLC | 38.65% | 0.01% | 1,664,595 | 1,664,595 | 100.00% | 599,254,000 | Mar 31, 2023 |
SABBY MANAGEMENT, LLC | 28.22% | 0.38% | 1,215,534 | 1,215,534 | 100.00% | 437,592,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 22.10% | 0.00% | 951,806 | 951,806 | 100.00% | 342,650,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 19.69% | 0.00% | 848,000 | 848,000 | 100.00% | 305,280,000 | Mar 31, 2023 |
AYRTON CAPITAL LLC | 17.77% | 0.99% | 765,425 | 765,425 | 100.00% | 275,553,000 | Mar 31, 2023 |
CVI HOLDINGS, LLC | 16.29% | 0.10% | 701,634 | 701,634 | 100.00% | 252,588,000 | Mar 31, 2023 |
BOOTHBAY FUND MANAGEMENT, LLC | 3.16% | 0.00% | 136,231 | 136,231 | 100.00% | 49,043,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.67% | - | 28,916 | -551 | -1.87% | 10,409,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 0.42% | - | 18,057 | - | - | 6,501,000 | Mar 31, 2023 |
NORTHERN TRUST CORP | 0.41% | - | 17,853 | 17,853 | 100.00% | 6,427,000 | Mar 31, 2023 |
RENAISSANCE TECHNOLOGIES LLC | 0.38% | - | 16,200 | 16,200 | 100.00% | 6,000 | Mar 31, 2023 |
BLACKROCK INC. | 0.30% | - | 13,104 | - | - | 4,718,000 | Mar 31, 2023 |
ADVISORY SERVICES NETWORK, LLC | 0.27% | 0.00% | 11,438 | 2,116 | 22.70% | 4,118,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.12% | 0.00% | 5,202 | -4,122 | -44.21% | 2,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.03% | - | 1,141 | - | - | 411,000 | Mar 31, 2023 |
IFP ADVISORS, INC | 0.00% | - | 142 | - | - | 244,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 59 | 9 | 18.00% | 21,000 | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | 2 | - | - | 1,000 | Mar 31, 2023 |
MARINER, LLC | - | - | - | -13,533 | -100.00% | - | Mar 31, 2023 |
Sonnet BioTherapeutics's largest institutional shareholder is ANSON FUNDS MANAGEMENT LP, holding 40.87% of the company's total share outstanding, currently valued at $633.60M. The top 10 institutional shareholders own together 187.85% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
AYRTON CAPITAL LLC | 17.77% | 0.99% | 765,425 | 765,425 | 100.00% | 275,553,000 | Mar 31, 2023 |
SABBY MANAGEMENT, LLC | 28.22% | 0.38% | 1,215,534 | 1,215,534 | 100.00% | 437,592,000 | Mar 31, 2023 |
ANSON FUNDS MANAGEMENT LP | 40.87% | 0.10% | 1,760,000 | 1,760,000 | 100.00% | 633,600,000 | Mar 31, 2023 |
CVI HOLDINGS, LLC | 16.29% | 0.10% | 701,634 | 701,634 | 100.00% | 252,588,000 | Mar 31, 2023 |
WALLEYE CAPITAL LLC | 38.65% | 0.01% | 1,664,595 | 1,664,595 | 100.00% | 599,254,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 22.10% | 0.00% | 951,806 | 951,806 | 100.00% | 342,650,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 19.69% | 0.00% | 848,000 | 848,000 | 100.00% | 305,280,000 | Mar 31, 2023 |
BOOTHBAY FUND MANAGEMENT, LLC | 3.16% | 0.00% | 136,231 | 136,231 | 100.00% | 49,043,000 | Mar 31, 2023 |
ADVISORY SERVICES NETWORK, LLC | 0.27% | 0.00% | 11,438 | 2,116 | 22.70% | 4,118,000 | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.12% | 0.00% | 5,202 | -4,122 | -44.21% | 2,000 | Mar 31, 2023 |
IFP ADVISORS, INC | 0.00% | - | 142 | - | - | 244,000 | Mar 31, 2023 |
RENAISSANCE TECHNOLOGIES LLC | 0.38% | - | 16,200 | 16,200 | 100.00% | 6,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.67% | - | 28,916 | -551 | -1.87% | 10,409,000 | Mar 31, 2023 |
NORTHERN TRUST CORP | 0.41% | - | 17,853 | 17,853 | 100.00% | 6,427,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 0.42% | - | 18,057 | - | - | 6,501,000 | Mar 31, 2023 |
BLACKROCK INC. | 0.30% | - | 13,104 | - | - | 4,718,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.03% | - | 1,141 | - | - | 411,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 59 | 9 | 18.00% | 21,000 | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | 2 | - | - | 1,000 | Mar 31, 2023 |
MARINER, LLC | - | - | - | -13,533 | -100.00% | - | Mar 31, 2023 |
The largest Sonnet BioTherapeutics shareholder by % of total assets is AYRTON CAPITAL LLC. The company owns 765.42K shares of Sonnet BioTherapeutics (SONN), representing 0.99% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ANSON FUNDS MANAGEMENT LP | 40.87% | 0.10% | 1,760,000 | 1,760,000 | 100.00% | 633,600,000 | Mar 31, 2023 |
WALLEYE CAPITAL LLC | 38.65% | 0.01% | 1,664,595 | 1,664,595 | 100.00% | 599,254,000 | Mar 31, 2023 |
SABBY MANAGEMENT, LLC | 28.22% | 0.38% | 1,215,534 | 1,215,534 | 100.00% | 437,592,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 22.10% | 0.00% | 951,806 | 951,806 | 100.00% | 342,650,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 19.69% | 0.00% | 848,000 | 848,000 | 100.00% | 305,280,000 | Mar 31, 2023 |
AYRTON CAPITAL LLC | 17.77% | 0.99% | 765,425 | 765,425 | 100.00% | 275,553,000 | Mar 31, 2023 |
CVI HOLDINGS, LLC | 16.29% | 0.10% | 701,634 | 701,634 | 100.00% | 252,588,000 | Mar 31, 2023 |
BOOTHBAY FUND MANAGEMENT, LLC | 3.16% | 0.00% | 136,231 | 136,231 | 100.00% | 49,043,000 | Mar 31, 2023 |
NORTHERN TRUST CORP | 0.41% | - | 17,853 | 17,853 | 100.00% | 6,427,000 | Mar 31, 2023 |
RENAISSANCE TECHNOLOGIES LLC | 0.38% | - | 16,200 | 16,200 | 100.00% | 6,000 | Mar 31, 2023 |
ADVISORY SERVICES NETWORK, LLC | 0.27% | 0.00% | 11,438 | 2,116 | 22.70% | 4,118,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 59 | 9 | 18.00% | 21,000 | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | 2 | - | - | 1,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.03% | - | 1,141 | - | - | 411,000 | Mar 31, 2023 |
BLACKROCK INC. | 0.30% | - | 13,104 | - | - | 4,718,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 0.42% | - | 18,057 | - | - | 6,501,000 | Mar 31, 2023 |
IFP ADVISORS, INC | 0.00% | - | 142 | - | - | 244,000 | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.67% | - | 28,916 | -551 | -1.87% | 10,409,000 | Mar 31, 2023 |
UBS GROUP AG | - | - | - | -2,815 | -100.00% | - | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.12% | 0.00% | 5,202 | -4,122 | -44.21% | 2,000 | Mar 31, 2023 |
As of Mar 31 2023, Sonnet BioTherapeutics's largest institutional buyer is ANSON FUNDS MANAGEMENT LP. The company purchased 1.76M stocks of SONN, valued at $633.60M.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
TWO SIGMA SECURITIES, LLC | - | - | - | -18,003 | -100.00% | - | Mar 31, 2023 |
HRT FINANCIAL LP | - | - | - | -15,930 | -100.00% | - | Mar 31, 2023 |
MARINER, LLC | - | - | - | -13,533 | -100.00% | - | Mar 31, 2023 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.12% | 0.00% | 5,202 | -4,122 | -44.21% | 2,000 | Mar 31, 2023 |
UBS GROUP AG | - | - | - | -2,815 | -100.00% | - | Mar 31, 2023 |
GEODE CAPITAL MANAGEMENT, LLC | 0.67% | - | 28,916 | -551 | -1.87% | 10,409,000 | Mar 31, 2023 |
IFP ADVISORS, INC | 0.00% | - | 142 | - | - | 244,000 | Mar 31, 2023 |
VANGUARD GROUP INC | 0.42% | - | 18,057 | - | - | 6,501,000 | Mar 31, 2023 |
BLACKROCK INC. | 0.30% | - | 13,104 | - | - | 4,718,000 | Mar 31, 2023 |
MORGAN STANLEY | 0.03% | - | 1,141 | - | - | 411,000 | Mar 31, 2023 |
BANK OF AMERICA CORP /DE/ | - | - | 2 | - | - | 1,000 | Mar 31, 2023 |
WELLS FARGO & COMPANY/MN | 0.00% | - | 59 | 9 | 18.00% | 21,000 | Mar 31, 2023 |
ADVISORY SERVICES NETWORK, LLC | 0.27% | 0.00% | 11,438 | 2,116 | 22.70% | 4,118,000 | Mar 31, 2023 |
RENAISSANCE TECHNOLOGIES LLC | 0.38% | - | 16,200 | 16,200 | 100.00% | 6,000 | Mar 31, 2023 |
NORTHERN TRUST CORP | 0.41% | - | 17,853 | 17,853 | 100.00% | 6,427,000 | Mar 31, 2023 |
BOOTHBAY FUND MANAGEMENT, LLC | 3.16% | 0.00% | 136,231 | 136,231 | 100.00% | 49,043,000 | Mar 31, 2023 |
CVI HOLDINGS, LLC | 16.29% | 0.10% | 701,634 | 701,634 | 100.00% | 252,588,000 | Mar 31, 2023 |
AYRTON CAPITAL LLC | 17.77% | 0.99% | 765,425 | 765,425 | 100.00% | 275,553,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 19.69% | 0.00% | 848,000 | 848,000 | 100.00% | 305,280,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 22.10% | 0.00% | 951,806 | 951,806 | 100.00% | 342,650,000 | Mar 31, 2023 |
As of Mar 31 2023, Sonnet BioTherapeutics's biggest institutional seller is TWO SIGMA SECURITIES, LLC. The company sold -18.00K shares of SONN, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ANSON FUNDS MANAGEMENT LP | 40.87% | 0.10% | 1,760,000 | 1,760,000 | 100.00% | 633,600,000 | Mar 31, 2023 |
WALLEYE CAPITAL LLC | 38.65% | 0.01% | 1,664,595 | 1,664,595 | 100.00% | 599,254,000 | Mar 31, 2023 |
SABBY MANAGEMENT, LLC | 28.22% | 0.38% | 1,215,534 | 1,215,534 | 100.00% | 437,592,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 22.10% | 0.00% | 951,806 | 951,806 | 100.00% | 342,650,000 | Mar 31, 2023 |
ALYESKA INVESTMENT GROUP, L.P. | 19.69% | 0.00% | 848,000 | 848,000 | 100.00% | 305,280,000 | Mar 31, 2023 |
AYRTON CAPITAL LLC | 17.77% | 0.99% | 765,425 | 765,425 | 100.00% | 275,553,000 | Mar 31, 2023 |
CVI HOLDINGS, LLC | 16.29% | 0.10% | 701,634 | 701,634 | 100.00% | 252,588,000 | Mar 31, 2023 |
BOOTHBAY FUND MANAGEMENT, LLC | 3.16% | 0.00% | 136,231 | 136,231 | 100.00% | 49,043,000 | Mar 31, 2023 |
NORTHERN TRUST CORP | 0.41% | - | 17,853 | 17,853 | 100.00% | 6,427,000 | Mar 31, 2023 |
RENAISSANCE TECHNOLOGIES LLC | 0.38% | - | 16,200 | 16,200 | 100.00% | 6,000 | Mar 31, 2023 |
Sonnet BioTherapeutics's largest new institutional shareholder by number of shares is ANSON FUNDS MANAGEMENT LP, purchased 1.76M shares, valued at $633.60M, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
TWO SIGMA SECURITIES, LLC | - | - | - | -18,003 | -100.00% | - | Mar 31, 2023 |
HRT FINANCIAL LP | - | - | - | -15,930 | -100.00% | - | Mar 31, 2023 |
MARINER, LLC | - | - | - | -13,533 | -100.00% | - | Mar 31, 2023 |
UBS GROUP AG | - | - | - | -2,815 | -100.00% | - | Mar 31, 2023 |
Sonnet BioTherapeutics's largest sold out institutional shareholder by shares sold is TWO SIGMA SECURITIES, LLC, sold -18.00K shares, valued at -, as of undefined.
Sonnet BioTherapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
FIDELITY COMMONWEALTH TRUST | 0.15% | 467,345 | - | - | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 1,873,368 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 705,533 | - | - | Feb 29, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 9,159 | 1,507 | 19.69% | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 14,726 | -14,726 | -50.00% | Mar 31, 2024 |
EQ ADVISORS TRUST | 0.00% | 3,763 | - | - | Mar 31, 2024 |
Sonnet BioTherapeutics's largest mutual fund holder by % of total assets is "FIDELITY COMMONWEALTH TRUST", owning 467.35K shares, compromising 0.15% of its total assets.
Sonnet BioTherapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
30 Sep, 22 | 1 | -94.44% |
30 Jun, 22 | 18 | -14.29% |
31 Mar, 22 | 21 | 31.25% |
31 Dec, 21 | 16 | 23.08% |
30 Sep, 21 | 13 | 30.00% |
30 Jun, 21 | 10 | -33.33% |
31 Mar, 21 | 15 | 66.67% |
31 Dec, 20 | 9 | - |
30 Sep, 20 | 9 | 125.00% |
30 Jun, 20 | 4 | - |
As of 30 Sep 22, 1 institutions are holding Sonnet BioTherapeutics's shares, representing a decrease of -94.44% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
30 Sep, 22 | 2,000 | -99.94% |
30 Jun, 22 | 3,519,106 | -41.21% |
31 Mar, 22 | 5,985,793 | 50.03% |
31 Dec, 21 | 3,989,736 | 42.96% |
30 Sep, 21 | 2,790,790 | 164.02% |
30 Jun, 21 | 1,057,042 | 45.87% |
31 Mar, 21 | 724,669 | 58.56% |
31 Dec, 20 | 457,020 | 20.52% |
30 Sep, 20 | 379,210 | 49.70% |
30 Jun, 20 | 253,320 | - |
Sonnet BioTherapeutics (SONN) has 2.00K shares outstanding as of 30 Sep 22, down -99.94% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
30 Sep, 22 | 0.05% | 0.00% |
30 Jun, 22 | 92.66% | 0.37% |
31 Mar, 22 | 157.61% | 1.43% |
31 Dec, 21 | 105.06% | 1.95% |
30 Sep, 21 | 73.49% | 9.49% |
30 Jun, 21 | 27.83% | 7.64% |
31 Mar, 21 | 19.08% | 13.18% |
31 Dec, 20 | 12.03% | 12.07% |
30 Sep, 20 | 9.99% | 22.44% |
30 Jun, 20 | 6.67% | - |
As of 30 Sep 22, Sonnet BioTherapeutics is held by 0.05% institutional shareholders, representing a 0.00% growth compared to 30 Jun 22.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
30 Sep, 22 | - | -100.00% |
30 Jun, 22 | 6 | -53.85% |
31 Mar, 22 | 13 | 62.50% |
31 Dec, 21 | 8 | 33.33% |
30 Sep, 21 | 6 | 50.00% |
30 Jun, 21 | 4 | -60.00% |
31 Mar, 21 | 10 | 11.11% |
31 Dec, 20 | 9 | 28.57% |
30 Sep, 20 | 7 | 75.00% |
30 Jun, 20 | 4 | - |
- institutional shareholders have increased their position in SONN stock as of 30 Sep 22 compared to 6 in the previous quarter (a -100.00% decrease).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
30 Sep, 22 | - | -100.00% |
30 Jun, 22 | 6 | 100.00% |
31 Mar, 22 | 3 | 200.00% |
31 Dec, 21 | 1 | - |
30 Sep, 21 | 1 | - |
30 Jun, 21 | 1 | - |
31 Mar, 21 | 1 | - |
31 Dec, 20 | - | -100.00% |
30 Sep, 20 | 2 | - |
30 Jun, 20 | - | - |
- institutional shareholders have reduced their position in SONN stock as of 30 Sep 22 compared to 6 in the previous quarter (a -100.00% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
30 Sep, 22 | 1 | -94.44% | 2,000 | -99.94% | 0.05% | 0.00% | - | -100.00% | - | -100.00% |
30 Jun, 22 | 18 | -14.29% | 3,519,106 | -41.21% | 92.66% | 0.37% | 6 | -53.85% | 6 | 100.00% |
31 Mar, 22 | 21 | 31.25% | 5,985,793 | 50.03% | 157.61% | 1.43% | 13 | 62.50% | 3 | 200.00% |
31 Dec, 21 | 16 | 23.08% | 3,989,736 | 42.96% | 105.06% | 1.95% | 8 | 33.33% | 1 | - |
30 Sep, 21 | 13 | 30.00% | 2,790,790 | 164.02% | 73.49% | 9.49% | 6 | 50.00% | 1 | - |
30 Jun, 21 | 10 | -33.33% | 1,057,042 | 45.87% | 27.83% | 7.64% | 4 | -60.00% | 1 | - |
31 Mar, 21 | 15 | 66.67% | 724,669 | 58.56% | 19.08% | 13.18% | 10 | 11.11% | 1 | - |
31 Dec, 20 | 9 | - | 457,020 | 20.52% | 12.03% | 12.07% | 9 | 28.57% | - | -100.00% |
30 Sep, 20 | 9 | 125.00% | 379,210 | 49.70% | 9.99% | 22.44% | 7 | 75.00% | 2 | - |
30 Jun, 20 | 4 | - | 253,320 | - | 6.67% | - | 4 | - | - | - |
Sonnet BioTherapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of Sonnet BioTherapeutics's stock was made by Markey John on Sep 07 2023, selling - shares at - per share (valued at -). The last insider buy of SONN was made by Rao Raghu on Oct 27 2023, buying 31,250 shares at $1.60 per share (worth $50.00K).
Sonnet BioTherapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q4 2023 | 4 | - | - |
Q3 2023 | - | 1 | - |
Q2 2023 | 4 | - | - |
Q1 2023 | 5 | 6 | 83.33% |
Q4 2022 | 10 | - | - |
Q3 2022 | - | - | - |
Q2 2022 | - | 1 | - |
Q4 2021 | 8 | - | - |
Q2 2021 | 4 | 3 | 133.33% |
Q1 2021 | 1 | - | - |
Q3 2020 | 9 | - | - |
Q2 2020 | 13 | - | - |
Q1 2020 | 4 | - | - |
Q4 2019 | 5 | 1 | 500.00% |
Q3 2019 | 3 | - | - |
Q2 2019 | 23 | 3 | 766.67% |
Q1 2019 | 2 | - | - |
Q4 2018 | 14 | 3 | 466.67% |
Q3 2018 | 5 | - | - |
Q2 2018 | 8 | 18 | 44.44% |
4 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Sonnet BioTherapeutics's insiders, as of Q4 2023.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q4 2023 | 4 | - | - |
Q3 2023 | - | - | - |
Q2 2023 | 4 | - | - |
Q1 2023 | 1 | - | - |
Q4 2022 | - | - | - |
Q3 2022 | - | - | - |
Q2 2022 | - | - | - |
Q4 2021 | - | - | - |
Q2 2021 | 4 | - | - |
Q1 2021 | - | - | - |
Q3 2020 | - | - | - |
Q2 2020 | 2 | - | - |
Q1 2020 | 4 | - | - |
Q4 2019 | 4 | - | - |
Q3 2019 | 3 | - | - |
Q2 2019 | 5 | - | - |
Q1 2019 | 2 | - | - |
Q4 2018 | 14 | - | - |
Q3 2018 | 2 | - | - |
Q2 2018 | 5 | 18 | 27.78% |
As of Q4 2023, Insider owners conducted 4 open market buy trades and 0 open market sell trades of Sonnet BioTherapeutics's stocks.
SONN Ownership FAQ
Who Owns Sonnet BioTherapeutics?
Sonnet BioTherapeutics is owned by institutional shareholders (0.05%), insiders (5.44%), and public (94.51%). The largest institutional shareholder of Sonnet BioTherapeutics is ANSON FUNDS MANAGEMENT LP (40.87% of total shares) and the top mutual fund owner is FIDELITY COMMONWEALTH TRUST (0.15% of total shares).
Who are the major institutional shareholders of Sonnet BioTherapeutics?
Sonnet BioTherapeutics's major institutional shareholders are ANSON FUNDS MANAGEMENT LP, WALLEYE CAPITAL LLC, SABBY MANAGEMENT, LLC, ALYESKA INVESTMENT GROUP, L.P., and ALYESKA INVESTMENT GROUP, L.P.. The top five shareholders own together 149.53% of the company's share outstanding.
How many Sonnet BioTherapeutics shareholders are there?
As of Sep 2022, there are 1 institutional shareholders of Sonnet BioTherapeutics.
What percentage of Sonnet BioTherapeutics is owned by ANSON FUNDS MANAGEMENT LP?
ANSON FUNDS MANAGEMENT LP owns 1.76M shares of Sonnet BioTherapeutics, representing 40.87% of the company's total shares outstanding, valued at $633.6M (as of Mar 2023).
What percentage of Sonnet BioTherapeutics is owned by WALLEYE CAPITAL LLC?
As of Mar 2023, WALLEYE CAPITAL LLC holds 1.66M shares of Sonnet BioTherapeutics (SONN), compromising 38.65% of the company, valued at $599.25M.
What percentage of Sonnet BioTherapeutics is owned by SABBY MANAGEMENT, LLC?
SABBY MANAGEMENT, LLC is the third largest holder of Sonnet BioTherapeutics. The company owns 1.22M of the company's shares outstanding (worth $437.59M).